Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS

(NOVN)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
10/11/2019 10/14/2019 10/15/2019 10/16/2019 10/17/2019 Date
86.69(c) 85.96(c) 86.33(c) 86.4(c) 86.14 Last
4 757 807 4 512 967 4 761 567 4 524 373 6 037 863 Volume
+1.51% -0.84% +0.43% +0.08% -0.30% Change
More quotes
Financials (USD)
Sales 2019 46 902 M
EBIT 2019 13 829 M
Net income 2019 9 642 M
Debt 2019 17 034 M
Yield 2019 3,41%
Sales 2020 49 037 M
EBIT 2020 15 055 M
Net income 2020 9 707 M
Debt 2020 12 144 M
Yield 2020 3,54%
P/E ratio 2019 18,3x
P/E ratio 2020 19,9x
EV / Sales2019 4,61x
EV / Sales2020 4,31x
Capitalization 199 B
More Financials
Company
Novartis is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by family of products as follows: - pharmaceutical products (67.2%): used to treat cardiovascular, respiratory, and dermatological diseases, gastrointestinal... 
Sector
Pharmaceuticals
Calendar
10/22Earnings Release
More about the company
Surperformance© ratings of Novartis
Trading Rating : Investor Rating :
More Ratings
Latest news on NOVARTIS
10:59aINCYTE : Novartis announces that Jakavi meets primary endpoint in Phase III stud..
AQ
10:59aINCYTE : Announces that the REACH2 Pivotal Trial of Ruxolitinib Meets Primary En..
AQ
10/16NOVARTIS : announces that Jakavi® (ruxolitinib) meets primary endpoint in Phase ..
PU
10/16INCYTE : Says Phase 3 REACH2 Trial Meets Endpoint
DJ
10/16Factbox - How are businesses preparing for a 'no-deal Brexit'?
RE
10/15NOVARTIS : Sandoz and Pear Therapeutics announce Pear will solely commercialize ..
AQ
10/14EUROPE : European stocks hit pause as trade doubts linger
RE
10/11NOVARTIS : data show Cosentyx treatment results in rapid and sustained resolutio..
AQ
10/10NOVARTIS : data show Cosentyx® treatment results in rapid and sustained resoluti..
PU
10/09NOVARTIS : real-world evidence confirms high efficacy, long-term response and fa..
AQ
10/09NOVARTIS : STEP Program now accepting submissions for proposals that address unm..
AQ
10/09NOVARTIS : real-world evidence confirms high efficacy, long-term response and fa..
PU
10/08GSK recalls popular heartburn drug Zantac globally after cancer scare
RE
10/08NOVARTIS : data show more patients are completely symptom-free from chronic spon..
AQ
10/08NOVARTIS : receives FDA approval for Beovu, offering wet AMD patients vision gai..
AQ
More news
News in other languages on NOVARTIS
05:30aAktien Schweiz: SMI dreht leicht ins Plus - Temenos massiv unter Druck
05:30aBourse Zurich: le SMI passe dans le vert en fin de matinée
03:34aBourse Zurich: beaucoup de perdants, peu de gagnants et quelques indécis
02:45aBourse Zurich: Lonza et surtout Nestlé maintiennent l'illusion
12:31aZURICH STOCK EXCHANGE : 4-Wochenvorschau Schweiz
More news
Analyst Recommendations on NOVARTIS
More recommendations
Sector news : Pharmaceuticals - NEC
10:51aTEVA PHARMACEUTICAL INDUSTRIES : UK arm recalls some batches of Ranitidine - Med..
RE
10:22aALLERGAN : Form 8.3 -
DJ
05:25aTeva to donate over $15 billion worth of drugs in opioid settlement - source
RE
02:49aJOHNSON & JOHNSON : J&J Seeks $4 Billion Opioid Settlement
DJ
10/16DRUG FIRMS OFFER TO SETTLE U.S. OPIO : sources
RE
More sector news : Pharmaceuticals - NEC
Chart NOVARTIS
Duration : Period :
Novartis Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 94,08  $
Last Close Price 86,84  $
Spread / Highest target 23,7%
Spread / Average Target 8,34%
Spread / Lowest Target -7,30%
EPS Revisions
Managers
NameTitle
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Elizabeth Theophille Chief Technology & Digital Officer
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS16.20%198 756
JOHNSON & JOHNSON2.94%356 736
ROCHE HOLDING AG17.38%245 163
MERCK AND COMPANY10.52%216 224
PFIZER-16.75%200 998
NOVO NORDISK AS18.97%122 115